Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Eileen Francis
FDA has yet to finalize about one-third of its OTC monographs and several hundred ingredients do not have a final GRASE determination. Sorting will help the agency determine which of the 800 active OTC monograph ingredients are designated as needing more information to establish GRASE under a faster system based on administrative orders.
Johnson & Johnson will launch a Listerine mouthwash incorporating a class II device to address tooth sensitivity, Chief Technology Officer John Ghaim said during J&J’s Medical Devices & Consumer Analyst Day May 16. The company plans to launch 150 new products globally in 2018, which should help the company achieve sales ahead of the consumer health category.
J&J will launch a Listerine mouthwash in a formulation considered a medical device and indicated for tooth sensitivity and enter the premium baby care segment with the Petite Planet line. It plans to launch 150 products globally in 2018.
Federal agencies have “put brakes on new regulations” during the Trump administration and made efforts toward deregulation across the board, bringing about a “good and friendly environment for most businesses and industries,” says lobbyist Pete Evich. “We need to be careful about complacency that has a tendency to creep back in at a time like this when direct attacks and threats are down,” he said in a recent webinar.
Carma Labs’ Carmex Cold Sore Treatment claims did not mirror language in two OTC monographs for its active ingredients, the National Advertising Division says in a review of packaging and advertising claims challenged by GlaxoSmithKline's consumer business.
Market-leading feminine cleansing and douche brand and other products added in Prestige Brands' 2017 acquisition of CB Fleet helped drive its North American OTC health care revenues up 6.6% to $212.1m in its fiscal 2018 fourth quarter. Full-year revenues for the division in North America grew 20.5% to $868.9m fueled by the addition of the Fleet business and consumption growth in the firm’s core OTC brands, Prestige Brands said.